



## PRESS RELEASE

August 2, 2022

# Ziccum appoints new Scientific Director

**Ziccum AB has appointed a Scientific Director, as part of a major reorganisation aiming to facilitate and accelerate its new strategic focus on key projects and vaccine platforms. Ziccum Senior Formulation Specialist Fabrice Rose will assume the new role. The reorganization was implemented on August 1, 2022.**

Ziccum AB has appointed Fabrice Rose, until recently its Senior Formulation Specialist, as its new Scientific Director. Fabrice Rose is the author or co-author of 16 peer-reviewed publications on vaccine formulation. His 20 years' plus experience in formulation and drug delivery includes ten year's lab work specializing in the design and characterization of nanoparticulate vaccine formulations and investigating the physical stability of protein antigens.

### Strong team focus

The reorganisation, the result of extensive consultation and collaboration, is an integral part of Ziccum's new sharpened strategic focus, initiated with the arrival of new CEO Ann Gidner in May 2022. It has created new roles and clarified existing ones as the company deepens its project work and targets three key vaccine platforms.

CEO Ann Gidner: "I warmly welcome Fabrice to his new role. This reorganization will help us harness the great competence and commitment we have in-house in the best possible way. With a clear company focus and well-defined roles we can move ahead more efficiently and achieve great results together."

**For more information about Ziccum, please contact:**

---

Ann Gidner,  
CEO Ziccum  
Mail: [gidner@ziccum.com](mailto:gidner@ziccum.com)  
Mobile: +46 722140141

Fredrik Sjövall,  
Chairman of the Board, Ziccum AB  
Mail: [sjovall@ziccum.com](mailto:sjovall@ziccum.com)  
Mobile: +46 706 45 08 75

**Certified Adviser**  
Erik Penser Bank AB  
Mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)  
Phone: +46 8 463 83 00

## About Ziccum

---

### About Ziccum

Ziccum is developing new thermostable versions of vaccines and biologic materials for licensing to vaccine providers, developers, manufactures and CDMOs in the global pharmaceutical industry. Ziccum's patented drying technology, LaminarPace, is unique. It can dry-formulate temperature-sensitive vaccine materials at room temperature with high yields and low waste. These robust, thermostable dry powders could be stored and transported worldwide with no need for cold chain refrigeration or freezing. Ziccum is listed on the Nasdaq First North Growth Market

### Image Attachments

---

[DSC 8606](#)

### Attachments

---

[Ziccum appoints new Scientific Director](#)